Trial reportHaematologica2017
CD56
Abstract readClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.Blood · 2020Trial
- Advances in Cell Therapy for Chronic Graft-versus-Host Disease: Prophylactic and Therapeutic Perspectives.Clinical and experimental medicine · 2026Review
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.Blood advances · 2023Article
- CD56bright CD16- natural killer cells as an important regulatory mechanism in chronic graft-Haematologica · 2023Article
- Complex interactions of cellular players in chronic Graft-versus-Host Disease.Frontiers in immunology · 2023Review
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.Transplantation and cellular therapy · 2021Article
- Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.Frontiers in immunology · 2021Review
- Should we use extracorporeal photopheresis more often? Evidence from graft-versus-host disease patients monitored with Treg as a biomarker.Future science OA · 2020Article
- "Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation".Frontiers in immunology · 2020Article
- [Efficacy and peripheral immunity analysis of allogeneic natural killer cells therapy in patients with hepatocellular carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019Article
- Biomarkers in chronic graft-versus-host disease: quo vadis?Bone marrow transplantation · 2018Article
- The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.Expert review of clinical immunology · 2018Review
- Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence.Mediators of inflammation · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Amina KariminiaMichael Cuccione Childhood Cancer research Program, BC Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Sabine IvisonMichael Cuccione Childhood Cancer research Program, BC Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Bernard NgDepartment of Statistics, University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada.
Jacob RozmusMichael Cuccione Childhood Cancer research Program, BC Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Susanna SungMichael Cuccione Childhood Cancer research Program, BC Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Avani VarshneyMichael Cuccione Childhood Cancer research Program, BC Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Mahmoud AljurfKing Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
Sylvie LachanceHôpital Maisonneuve-Rosemont, Université de Montréal, QC, Canada.
Irwin WalkerHamilton Health Sciences Centre and McMaster University, Hamilton, ON, Canada.
Cindy TozeLeukemia/Bone Marrow Transplant Program of BC, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.
Jeff LiptonPrincess Margaret Cancer Centre University of Toronto, ON, Canada.
Stephanie J LeeFred Hutchinson Cancer Research Centre, Seattle, WA, USA.
Jeff SzerRoyal Melbourne Hospital and University of Melbourne, Australia.
Richard DooceyAuckland City and Starship Children's Hospital, Auckland, New Zealand.
Ian LewisInstitute of Medical and Veterinary Sciences, Adelaide, Australia.
Clayton SmithGeneral Hematology, Blood Cancers and Bone Marrow Transplant Program, University of Colorado Hospital, Aurora, CO, USA.
Naeem ChaudhriKing Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
Megan K LevingsBC Children's Hospital Research Institute and Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
Raewyn BroadyLeukemia/Bone Marrow Transplant Program of BC, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.
Gerald DevinsPrincess Margaret Cancer Centre University of Toronto, ON, Canada.
David SzwajcerCancerCare Manitoba, Winnipeg, MB, Canada.
Ronan FoleyHamilton Health Sciences Centre and McMaster University, Hamilton, ON, Canada.
Sara MostafaviDepartment of Statistics, University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada.
Steven PavleticCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Donna A WallThe Hospital for Sick Children and University of Toronto, ON, Canada.
Stephan CoubanNova Scotia Health Authority and Dalhousie University, Halifax, NS, Canada.
Tony PanzarellaPrincess Margaret Cancer Centre University of Toronto, ON, Canada.
Kirk R SchultzMichael Cuccione Childhood Cancer research Program, BC Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada kschultz@mail.ubc.ca.
Funding
Transplantation of G-CSF Stimulated Marrow vs BloodR01CA108752 · NCI · UNIVERSITY OF BRITISH COLUMBIA · PI SCHULTZ, KIRK R · 2006 to 2011
$2.4MNCI NIH HHS R01 CA108752
Abstract
Randomized trials have conclusively shown higher rates of chronic graft-
Indexed as
Hematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationAdolescentAdultAgedBiomarkersCD4-Positive T-LymphocytesCD56 AntigenChronic DiseaseFemaleFilgrastimGraft vs Host DiseaseHumansImmunophenotypingInterferon-gammaKiller Cells, NaturalBiomarkersCD56 AntigenFilgrastimInterferon-gamma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.